|
[1]
|
Einarson, T.R., Acs, A., Ludwig, C. and Panton, U.H. (2018) Prevalence of Cardiovascular Disease in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence from across the World in 2007-2017. Cardiovascular Diabetology, 17, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Xiao, Y., Yu, B., Chao, C., Wang, S., Hu, D., Wu, C., et al. (2024) Chinese Expert Consensus on Blood Lipid Management in Patients with Diabetes (2024 Edition). Journal of Translational Internal Medicine, 12, 325-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
American Diabetes Association (2019) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S14-S31. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Cai, C., Liu, Y., Li, Y., Shi, Y., Zou, H., Bao, Y., et al. (2022) Effectiveness of Quality of Care for Patients with Type 2 Diabetes in China: Findings from the Shanghai Integration Model (SIM). Frontiers of Medicine, 16, 126-138. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Tsai, I., Wang, C., Lu, Y., Hung, W., Wu, C., Lu, L., et al. (2017) The Burden of Major Adverse Cardiac Events in Patients with Coronary Artery Disease. BMC Cardiovascular Disorders, 17, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Duan, D., Kengne, A.P. and Echouffo-Tcheugui, J.B. (2021) Screening for Diabetes and Prediabetes. Endocrinology and Metabolism Clinics of North America, 50, 369-385. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Au Yeung, S.L., Luo, S. and Schooling, C.M. (2018) The Impact of Glycated Hemoglobin (HbA1c) on Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank. Diabetes Care, 41, 1991-1997. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
李亚冬, 李雅君. 不同糖代谢状态下糖化血红蛋白与冠心病的相关性研究[J]. 心肺血管病杂志, 2023, 32(1): 53-56.
|
|
[9]
|
Jiao, X., Zhang, Q., Peng, P. and Shen, Y. (2023) Hba1c Is a Predictive Factor of Severe Coronary Stenosis and Major Adverse Cardiovascular Events in Patients with Both Type 2 Diabetes and Coronary Heart Disease. Diabetology & Metabolic Syndrome, 15, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
何健祥. 糖化血红蛋白在2型糖尿病诊断和治疗中的应用价值研究[J]. 检验医学与临床, 2020, 17(5): 695-697.
|
|
[11]
|
中国老年学和老年医学学会. 老年冠心病慢病管理指南[J]. 中西医结合研究, 2023, 15(1): 30-42.
|
|
[12]
|
李雷, 孙怡咪, 刘刚. 冠脉CTA定量参数与冠心病患者疾病进展和预后的关系[J]. 海南医学, 2022, 33(20): 2672-2675.
|
|
[13]
|
Chen, J., Jiang, C., Guo, M., Zeng, Y., Jiang, Z., Zhang, D., et al. (2024) Effects of SGLT2 Inhibitors on Cardiac Function and Health Status in Chronic Heart Failure: A Systematic Review and Meta-Analysis. Cardiovascular Diabetology, 23, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Popoviciu, M., Păduraru, L., Yahya, G., Metwally, K. and Cavalu, S. (2023) Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences, 24, Article 10449. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Müller, T.D., Finan, B., Bloom, S.R., D’Alessio, D., Drucker, D.J., Flatt, P.R., et al. (2019) Glucagon-Like Peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Neuen, B.L., Heerspink, H.J.L., Vart, P., Claggett, B.L., Fletcher, R.A., Arnott, C., et al. (2024) Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria. Circulation, 149, 450-462. [Google Scholar] [CrossRef] [PubMed]
|